SAB Biotherapeutics Completes $118 Million Merger With Big Cypress Acquisition Corp.

Represented SAB Biotherapeutics, a clinical-stage biopharmaceutical company advancing a new class of immunotherapies, in its $118 million merger agreement with blank check company Big Cypress Acquisition Corp. (BCYP), and post-transaction the combined company plans to be listed on NASDAQ.  Upon closing of the proposed transaction, the combined company will operate as SAB Biotherapeutics and will continue to operate under the SAB management team. SAB plans to be listed on NASDAQ following the closing of the transaction.